Spots Global Cancer Trial Database for Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

Official Title: A Pilot Study of Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis After Chemoradiotherapy For Stage III Non-Small Cell Lung Cancer

Study ID: NCT04040244

Conditions

Pneumonitis

Nonsmall Cell Lung Cancer Stage III

Interventions

Exhaled Breath Collection

Blood sample

Study Description

Brief Summary: This is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic pneumonitis.

Detailed Description: Primary Objective: • To quantify the intra-person variability of concentrations of TGF-β1, IL-6, IL-1α, and IL-10 measured in exhaled breath condensate. Secondary Objectives: * To examine the associations between differences in pre-treatment and post-treatment exhaled breath condensate concentrations of TGF-β1, IL-6, IL-1α, and IL-10 and the development of CTCAE grade 2+ symptomatic pneumonitis. * To examine the associations between serum measures of TGF-β1, IL-6, IL-1α, and IL-10 and: * Exhaled breath condensate measures of the same biomarkers, and * The development of CTCAE grade 2+ symptomatic pneumonitis. * To examine the association between microbiome signatures found in pre-treatment exhaled breath condensate and the development of CTCAE grade 2+ symptomatic pneumonitis.